I1-imidazoline binding site selective ligand and α2-adrenoceptor agonist. Possesses greater I1 vs α2 selectivity than the prototypical compound, clonidine. Also thought to enhance autophagy; shown to increase LC3-II levels in PC12 cells.
|Storage||Store at -20°C|
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
All Tocris products are intended for laboratory research use only.
|Solvent||Max Conc. mg/mL||Max Conc. mM|
Preparing Stock Solutions
The following data is based on the product molecular weight 238.29. Batch specific molecular weights may vary from batch to batch due to solvent of hydration, which will affect the solvent volumes required to prepare stock solutions.
|Concentration / Solvent Volume / Mass||1 mg||5 mg||10 mg|
|1 mM||4.2 mL||20.98 mL||41.97 mL|
|5 mM||0.84 mL||4.2 mL||8.39 mL|
|10 mM||0.42 mL||2.1 mL||4.2 mL|
|50 mM||0.08 mL||0.42 mL||0.84 mL|
References are publications that support the products' biological activity.
Bricca et al (1994) Human brain imidazoline receptors: Further characterisation with [3H] clonidine. Eur.J.Pharmacol. 266 25 PMID: 8137880
Bricca et al (1989) Rilmenidine selectivity for imidazoline receptors in human brain. Eur.J.Pharmacol. 163 373 PMID: 2566507
Mammoto et al (1996) Antiarrhythmic action of rilmenidine on adrenaline-induced arrhythmia via central imidazoline receptors in halothane-anaesthetized dogs. Br.J.Pharmacol. 117 1744 PMID: 8732285
Michel and Ernsberger (1992) Keeping an eye on the I site: imidazoline-preferring receptors. TiPS 13 369 PMID: 1413085
Williams et al (2008) Novel targets for Huntington's disease in an mTOR-independent autophagy pathway. Nat.Chem.Biol. 4 295 PMID: 18391949
If you know of a relevant reference for Rilmenidine hemifumarate, please let us know.
View Related Products by Target
View Related Products by Product Action
Keywords: Rilmenidine hemifumarate, supplier, α2-adrenoceptor, alpha2-adrenoceptor, a2-adrenoceptor, α2-Adrenergic, alpha2-Adrenergic, a2-adrenergic, agonists, I1, ligand, Receptors, Imidazoline, Adrenergic, Alpha-2, Receptors, I1, Receptors, Autophagy, Adrenergic, Alpha-2, Receptors, Tocris Bioscience
1 Citation for Rilmenidine hemifumarate
Citations are publications that use Tocris products. Selected citations for Rilmenidine hemifumarate include:
Sánchez-Blázquez et al (2000) Activation of I(2)-imidazoline receptors enhances supraspinal morphine analgesia in mice: a model to detect agonist and antagonist activities at these receptors. Br J Pharmacol 130 146 PMID: 10781010
Do you know of a great paper that uses Rilmenidine hemifumarate from Tocris? If so please let us know.
Reviews for Rilmenidine hemifumarate
There are currently no reviews for this product. Be the first to review Rilmenidine hemifumarate and earn rewards!
Have you used Rilmenidine hemifumarate?
Submit a review and receive an Amazon gift card.
$10US/$10CAN/€7/£6 gift card for a review without an image
$25US/$25CAN/€18/£15 gift card for a review with an image
*Offer only valid in the USA / Canada, UK and EuropeSubmit a Review
Literature in this Area
Tocris offers the following scientific literature in this area to showcase our products. We invite you to request* or download your copy today!
*Please note that Tocris will only send literature to established scientific business / institute addresses.
Major depressive disorder is characterized by depressed mood and a loss of interest and/or pleasure. Updated in 2015 this poster highlights presynaptic and postsynaptic targets for the potential treatment of major depressive disorder, as well as outlining the pharmacology of currently approved antidepressant drugs.
Peripheral sensitization is the reduction in the threshold of excitability of sensory neurons that results in an augmented response to a given external stimulus. This poster outlines the excitatory and inhibitory signaling pathways involved in modulation of peripheral sensitization. The role of ion channels, GPCRs, neurotrophins, and cytokines in sensory neurons are also described.
Parkinson's disease (PD) causes chronic disability and is the second most common neurodegenerative condition. This poster outlines the neurobiology of the disease, as well as highlighting current therapeutic treatments for symptomatic PD, and emerging therapeutic strategies to delay PD onset and progression.